Article Details

CTI BioPharma [NASDAQ: CTIC] Reveals FDA Extends Review Period for Pacritinib - MZP News

Retrieved on: 2021-12-01 06:41:54

Tags for this article:

Click the tags to see associated articles and topics

CTI BioPharma [NASDAQ: CTIC] Reveals FDA Extends Review Period for Pacritinib - MZP News. View article details on hiswai:

Excerpt

CTI BioPharma Corp. [NASDAQ: CTIC] disclosed that FDA has informed the company about the decision it has made regarding the NDA for Pacritinib.

Article found on: mzpnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up